Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE3

Total Enrollment

680 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula Realgar-Indigo naturalis Tablet combined with Imatinib will be compared with imatinib alone in adult patients with diagnosed Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in the chronic phase (CML-CP).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT04070443

Philadelphia Chromosome Positive CML BCR-ABL Positive Chronic Myelogenous Leukemia

ACTIVE_NOT_RECRUITING PHASE2

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

NCT00237120

Chronic Myelogenous Leukemia in Chronic Phase

COMPLETED PHASE3

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

NCT00103844

Chronic Myeloid Leukemia Philadelphia-Positive Myeloid Leukemia

COMPLETED PHASE2

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

NCT03459534

Chronic Myeloid Leukemia, Chronic Phase CML, Chronic Phase CML, Refractory +1 more

RECRUITING PHASE3

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

NCT00123487

Myeloid Leukemia, Chronic, Accelerated Phase Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Myelogenous Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Compound realgar natural indigo Tablet

Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.

imatinib,0.4g,qd

Group Type EXPERIMENTAL

Compound realgar natural indigo Tablet

Intervention Type DRUG

Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.

imatinib,0.4g,qd

placebo

placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.

imatinib 0.4g qd

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Compound realgar natural indigo Tablet

Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.

imatinib,0.4g,qd

Intervention Type DRUG

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients, age \>= 18 years and \<= 75 years.
2. Eastern Cooperative Oncology Group （ECOG） performance status (PS) score 0, 1, or 2.
3. Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome positive.(Ph+ CML-CP)
4. Ph+ Chronic myelogenous leukemia in chronic phase patients within the first 12 months of diagnosis.
5. Adequate end organ function as defined by:

(1). Alanine transaminase（ALT）, Aspartate transaminase（AST） \<=2.5 x upper limit of normal（ULN）.

(2). Total bilirubin \<= 1.5 x ULN. (3).Cr \<= 1.5 x ULN. (4). Serum amylase and lipase \<= 1.5 x ULN. 6. Signed informed consent.

Exclusion Criteria

1\. Previously received or be receiving any of the following medical treatment for CML:

1. . Treatment with Busulfan within 1 day prior to study entry.
2. . Treatment with interferon-alpha within 2 days prior to study entry.
3. . Treatment with hydroxyurea within 1 day prior to study entry.
4. . Treatment with homoharringtonine within 14 days prior to study entry.
5. . Treatment with Cytosine arabinoside within 28 days prior to study entry.
6. . Surgery (Including hematopoietic stem cell transplantation therapy)
7. . Treatment with anthracyclines, or etoposide within 21 days prior to study entry.

2\. Treatment with any tyrosine kinase inhibitor(s) or arsenic reagent prior to study entry 3. Patients who are: (a) pregnant, (b) breast feeding, (c) female or male of childbearing potential unwilling to use contraceptive precautions throughout the trial.

4\. Major surgery within 4 weeks prior to randomization or who have not recovered from prior surgery.

5\. Patients who have not recovered from toxic reaction of prior similar treatment evaluated by investigators.

6\. Impaired cardiac function including any one of the following:

1. LVEF \< 45%.
2. . Complete left bundle branch block.
3. . Use of a ventricular-paced pacemaker.
4. . Congenital long QT syndrome.
5. . History or presence of ventricular, clinically significant atrial tachyarrhythmias
6. . History or presence of clinically significant bradyarrhythmia.(heart rate persistently less than 50/min)
7. . QTcF \> 450 msec for male or 470 msec for female.
8. . History of clinically documented myocardial infarction or unstable angina (during the last 12 month).
9. .Any other severe heart disease. 7. Patients with active, uncontrolled psychiatric disorders, without insight and the ability of exact expression.

8\. Uncontrolled medical conditions:

1. .Uncontrolled diabetes with fasting blood-glucose \>200mg/dl (11.1mmol/L),or with combined symptoms (nephropathy, peripheral neuropathy).
2. . Uncontrolled hypertension.
3. . Active or uncontrolled infection (persistent fever and worsening of the clinical symptoms) 9. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the tested drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).

10\. History of chronic pancreatitis or history of acute pancreatitis within 1 year of study entry.

11\. Acute or chronic uncontrolled liver disease or severe renal disease considered unrelated to CML.

12\. Patients actively receiving therapy with strong CYP3A4 inhibitors, strong CYP3A4 inducers or any medications being potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.

13\. Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks prior to randomization.

14\. Known to be allergic to the study drugs, including crude drug or adjuvant. 15. As investigators evaluate, the patients do not fit to join the study (such as with severe complications) .

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No